Crinetics Pharmaceuticals CRNX Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -3,020.3%+3,694pp | -6,714.8%+24,415pp | -31,130.2%-738pp | -30,392.2%+19,178pp | -49,569.7%-16,956pp | |
| Net margin | -2,747.2%+3,299pp | -6,046.2%+21,517pp | -27,563.3%-995pp | -26,568.5%+16,623pp | -43,191.1%-14,470pp | |
| EBITDA margin | -2,997.5%+3,667pp | -6,664.2%+24,226pp | -30,890.2%-745pp | -30,144.9%+18,999pp | -49,143.9%-16,799pp | |
| Free cash flow margin | -2,321.7%+2,664pp | -4,985.5%+18,352pp | -23,337.1%-1,067pp | -22,269.8%+13,196pp | -35,465.9%-12,941pp | |
| Returns | ||||||
| Return on equity | -39.2%+1.0pp | -40.2%+4.2pp | -44.4%-7.5pp | -36.9%-6.1pp | -30.8%+1.2pp | |
| Return on assets | -35.9%+0.4pp | -36.3%+3.3pp | -39.7%-6.4pp | -33.2%-5.2pp | -28.1%+0.8pp | |
| Return on invested capital | -45.1%+5.4pp | -50.4%+10.2pp | -60.6%-12.3pp | -48.4%-5.1pp | -43.3%-2.1pp | |
| Efficiency | ||||||
| Asset turnover | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Liquidity | ||||||
| Current ratio | 18.6×+6.3× | 12.3×-2.8× | 15.1×-2.7× | 17.8×-4.7× | 22.5×-0.5× | |
| Quick ratio | 18.6×+6.3× | 12.3×-2.8× | 15.1×-2.7× | 17.8×-4.7× | 22.5×-0.5× | |
| Cash ratio | 1.6×+0.4× | 1.2×-0.3× | 1.5×+0.7× | 0.8×-0.9× | 1.7×-2.8× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $12.30+16.6% | $10.55-7.3% | $11.38-8.9% | $12.49-7.3% | $13.47-17.9% | |
| Valuation | ||||||
| Market capitalization | $3.8B-13.9% | $4.42B+12.6% | $3.92B+35.3% | $2.9B-7.1% | $3.12B-34.2% | |
| Enterprise value | $3.74B-14.4% | $4.36B+13.1% | $3.86B+33.3% | $2.89B-5.9% | $3.08B-32.1% | |
| Price / sales | 210.5×-363× | 574×-1,981× | 2,555.3×+473× | 2,082.2×-2,024× | 4,106.4×-457× | |
| Price / book | 3×-1.5× | 4.5×+0.8× | 3.7×+1.2× | 2.5×0.0× | 2.5×-1.1× | |
| EV / sales | 206.7×-360× | 567×-1,947× | 2,514.2×+435× | 2,079.5×-1,968× | 4,047.1×-311× | |
| Free cash flow yield | -11%-2.3pp | -8.7%+0.4pp | -9.1%+1.6pp | -10.7%-2.1pp | -8.6%-3.7pp | |
| Earnings yield | -13.1%-2.5pp | -10.5%+0.3pp | -10.8%+2.0pp | -12.8%-2.2pp | -10.5%-4.2pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Crinetics Pharmaceuticals's profit margins?
- Crinetics Pharmaceuticals (CRNX) runs a 150.0% gross margin and a -3020.3% operating margin, with a -2747.2% net margin.
- Where do Crinetics Pharmaceuticals's ratios come from?
- Every ratio is computed from Crinetics Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.